2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Thyroid Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Synovial
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Liposarcoma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Tongue Neoplasms
1
Tobacco Use Disorder
1
Thyroid Nodule
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Salivary Gland Neoplasms
1
Interventions
Adrenalectomy
5
Radiosurgery
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
FAPI-46
2
pertuzumab
1
olaparib
1
lutetium Lu 177 dotatate
1
iodophenyl metomidate
1
camrelizumab
1
apatinib
1
X-Rays
1
Surgical Procedures, Operative
1
Radiofrequency Ablation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Nephrectomy
1
N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
1
Molecular Diagnostic Techniques
1
Mitotane
1
Immunotherapy
1
Gefitinib
1
Floxuridine
1
Erlotinib Hydrochloride
1
Endosonography
1
Endoscopic Ultrasound-Guided Fine Needle Aspiration
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adrenal Gland Neoplasms
×
Molecular Diagnostic Techniques
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled